Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Glen Powell will host 'Saturday Night Live' with Olivia Dean as musical guest: What to know ahead of their debut - 2Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- 3Cyber Monday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- 4Surging measles cases are 'fire alarm' warning that other diseases could be next
- 5Step by step instructions to Recognize the Distinction Between Lab Jewels and Precious stone Simulants
- The Incomparable Advanced cameras: Which One Will Win?
- Blue Origin’s New Glenn rocket landed its booster on a barge at sea – an achievement that will broaden the commercial spaceflight market
- Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- The most effective method to Offset Album Rates with Liquidity Needs
- Craig the beer-ambassador elephant dies aged 54
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- The Longest Underwater Tunnel Connecting Germany and Denmark
- ‘Dying of thirst’: Inside Gaza’s al-Mawasi water crisis
